PNPLA3 and metabolic dysfunction-associated steatotic liver disease: We showed here that the LAMPS model recapitulates key phenotypes of early and late MASLD, along with key differences in the response to drug treatment in the LAMPS constructed with either wild-type or high-risk PNPLA3 alleles.